1
|
Yang J, Jiao J, Draheim KM, Yang G, Yang H, Yao LC, Shultz LD, Greiner DL, Rajagopal D, Vessillier S, Maier CC, Mohanan S, Cai D, Cheng M, Brehm MA, Keck JG. Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model. FASEB J 2023; 37:e22995. [PMID: 37219526 PMCID: PMC10242584 DOI: 10.1096/fj.202300040r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2023] [Revised: 04/18/2023] [Accepted: 05/12/2023] [Indexed: 05/24/2023]
Abstract
Immuno-oncology (IO)-based therapies such as checkpoint inhibitors, bi-specific antibodies, and CAR-T-cell therapies have shown significant success in the treatment of several cancer indications. However, these therapies can result in the development of severe adverse events, including cytokine release syndrome (CRS). Currently, there is a paucity of in vivo models that can evaluate dose-response relationships for both tumor control and CRS-related safety issues. We tested an in vivo PBMC humanized mouse model to assess both treatment efficacy against specific tumors and the concurrent cytokine release profiles for individual human donors after treatment with a CD19xCD3 bispecific T-cell engager (BiTE). Using this model, we evaluated tumor burden, T-cell activation, and cytokine release in response to bispecific T-cell-engaging antibody in humanized mice generated with different PBMC donors. The results show that PBMC engrafted NOD-scid Il2rgnull mice lacking expression of mouse MHC class I and II (NSG-MHC-DKO mice) and implanted with a tumor xenograft predict both efficacy for tumor control by CD19xCD3 BiTE and stimulated cytokine release. Moreover, our findings indicate that this PBMC-engrafted model captures variability among donors for tumor control and cytokine release following treatment. Tumor control and cytokine release were reproducible for the same PBMC donor in separate experiments. The PBMC humanized mouse model described here is a sensitive and reproducible platform that identifies specific patient/cancer/therapy combinations for treatment efficacy and development of complications.
Collapse
Affiliation(s)
- Jiwon Yang
- The Jackson Laboratory; Sacramento, CA, USA
| | - Jing Jiao
- The Jackson Laboratory; Sacramento, CA, USA
| | | | | | | | | | | | - Dale L. Greiner
- Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School; Worcester, MA, USA
| | - Deepa Rajagopal
- National Institute for Biological Standards and Control, Biotherapeutics Division; Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK
| | - Sandrine Vessillier
- National Institute for Biological Standards and Control, Biotherapeutics Division; Blanche Lane, South Mimms, Hertfordshire EN6 3QG, UK
| | - Curtis C. Maier
- Non Clinical Safety, GlaxoSmithKline plc; Collegeville, PA, USA
| | - Sunish Mohanan
- NonClinical Safety and Pathobiology, Gilead Sciences Inc’ Foster City, CA, USA
| | | | | | - Michael A. Brehm
- Program in Molecular Medicine, Diabetes Center of Excellence, University of Massachusetts Chan Medical School; Worcester, MA, USA
| | | |
Collapse
|